![]() Metabolic Solutions Development Metabolic Solutions Development Company (MSDC) is a company that discovers and develops molecular targets to treat metabolic diseases. | Kadimastem Kadimastem is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells (hESCs). | ||||
Founding Date | Founding Date 2011 | Founding Date 1989 | Founding Date 2006 | Founding Date 2017 | Founding Date 2009 |
Type | Type Public | Type Public | Type Private | Type Private | Type Public |
Tags | |||||
Locations | Locations Shanghai, CN HQ Beijing, CN Wuhan, CN Hong Kong, HK | Locations Macierzysz, PL HQ | Locations Kalamazoo, US HQ | Locations Basel, CH HQ | Locations Ness Ziona, IL HQ |
Employees | Employees 168 | Employees 361 | Employees 13 | Employees 10 | Employees 11 |
Financial | |||||
Revenue (est.) | Revenue (est.) ¥492.9m (FY, 2025) | Revenue (est.) zł282.5m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A |
Cost of goods | Cost of goods ¥180.1m (FY, 2025) | Cost of goods zł157.1m (FY, 2025) | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit ¥1.6b (FY, 2025) | Gross profit zł128.4m (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A |
Net income | Net income ¥1.1b (FY, 2025) | Net income zł3.4m (FY, 2025) | Net income N/A | Net income N/A | Net income (₪26.6m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 242.4m | Total funding raised N/A | Total funding raised $ 42.2m | Total funding raised $ 13.3m | Total funding raised N/A |
Bioton is a biotech company whose major therapeutic area is diabetes.
View company
Metabolic Solutions Development Company (MSDC) is a company that discovers and develops molecular targets to treat metabolic diseases.
View companyKadimastem is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from human embryonic stem cells (hESCs).
View company